Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

Detailed price information for Artelo Biosciences Inc (ARTL-Q) from The Globe and Mail including charting and trades.
FMIBlog

Dental Piezoelectric Ultrasonic Unit Market to Reach USD 431.9 Million by 2036 as China-Based Manufacturers Reshape Global Pricing Dynamics

Dental Piezoelectric Ultrasonic Unit Market is set to reach USD 265.1 million by 2026-end and grow at a CAGR of 5.0% between 2026-2036 ...
Las Vegas Sun

Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...